ClinicalTrials.gg
Enrolling by invitationNCT07384104Updated Feb 3, 2026

Compare the Pharmacokinetics, Pharmacodynamics, Safety and Immunogenicity of SAL023 and Italy-Manufactured Evenity in Healthy Subjects

A Phase 1 interventional study of SAL0123 and Romosozumab in Osteoporosis, sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd.. Enrolling by invitation at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-03.

Sponsored by Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 9 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.

Planned enrollment
30th of 57
118 · median 120
Started
2025
with 10 others
Phase 1
11 of 87
4 open now
Primary completion
2026-02
later than 10 of 32 live
Registered
80th of 87
by date
Lead sponsor
3 of 87
Shenzhen Salubris Pharmaceuticals Co., Ltd.

Among the 87 studies in Osteoporosis with a site in China, this one is the 30th largest by planned enrollment of the 57 interventional ones that give a count, is one of 11 that started in 2025, is one of 11 in phase 1, reaches primary completion later than 10 of the 32 other live ones, and was the 80th registered.

Osteoporosis

1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.

Browse Osteoporosis studies →

Open to participants now

27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:

21 more — sign in →

All 27 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies in Osteoporosis with a site in China, or all of them as a file.
02

Study summary

Primary objective of this study is to evaluate the similarity in pharmacokinetic characteristics between SAL023 Injection and Italy-manufactured Evenity. Secondary objective is to assess the similarity in safety, pharmacodynamic and immunogenicity profiles of SAL023 Injection and Italy-manufactured Evenity.

Read the detailed description

This study adopts a randomized, open-label, single-dose, active-controlled, two-arm, parallel-group design.

The entire study will last approximately 16 weeks, consisting of a screening period, a dosing and inpatient observation period, and a follow-up period. A total of 118 healthy adult Chinese subjects are planned to be enrolled in the study and will be randomly assigned to the SAL023 group (Group A) and the Italy-manufactured Evenity group (Group B) at a ratio of 1:1, with 59 subjects in each group. All subjects will receive a single subcutaneous injection of either SAL023 or Italy-manufactured Evenity.

Eligible subjects will be admitted to the research center on Day -1 and undergo randomization. They will receive the required examinations on Day 10 after dosing, and will be discharged from the research center only after the investigator confirms their safety. After discharge, the subjects will return to the research center for regular follow-up visits in accordance with the study protocol.

03

Conditions studied

  • Osteoporosis

Browse trials for

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • Safety
  • Immunogenicity
  • Biosimilarity Comparison
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Have a full understanding of the study, voluntarily sign the written form (ICF), and be able to comply with the requirements and restrictions specified in the ICF.
  2. Healthy Chinese male or female subjects.
  3. Aged 18 to 45 years old (inclusive of both endpoints).
  4. Body weight ≥ 50 kg and (BMI) ranging from 19.0 to 25.0 kg/m² (inclusive of both endpoints; BMI = weight ÷ height²).
  5. Results of all examinations (including physical examination, vital signs, blood routine, urine routine, blood biochemistry, coagulation function, myocardial enzymes, thyroid function, serum virology, 12-lead , chest X-ray (anteroposterior view), abdominal ultrasound, etc.) are normal or have minor abnormalities that are judged as not clinically insignificant by the investigator.
  6. The subject or their partner has no pregnancy plans during the study period and within 3 months after the last administration of the study drug, and voluntarily adopts effective measures (contraceptives are prohibited during the study period) to avoid pregnancy of themselves or their partner; in addition, the subject will not donate sperm or ova (egg cells, oocytes) for reproductive or assisted reproductive purposes.

Exclusion criteria

Exclusion Criteria:

  1. A history of acute drug or food allergic reactions within 2 weeks prior to screening; or allergic diathesis (e.g., allergy to two or more drugs, foods or pollen); or a history of allergic diseases (e.g., asthma, urticaria, eczematous dermatitis, etc.); or a possible or definite allergy to the study drug (including similar drugs or the control drug) and any of its , reactions, or clinically significant notable reactions as judged by the investigator.
  2. Positive result for any of the following tests: surface antigen, antibody, antibody, or treponema pallidum antibody.
  3. Bone mineral density T-score ≤ -2.5 at any of the following sites: lumbar vertebrae L1-L4 (total), total hip joint, or femoral neck during the screening period.
  4. Serum calcium, creatinine, free triiodothyronine (FT3), free thyroxine (FT4), thyroid stimulating hormone (TSH), or parathyroid hormone levels outside the normal reference range.
  5. A history of any of the following diseases: history of hip fracture or fracture at any other site within 6 months prior to the first administration; history of myocardial infarction; history of cerebral infarction or ischemic stroke.
  6. Use of any of the following foods, drugs or treatments prior to the first administration: estrogen/progesterone replacement therapy, calcitonin, parathyroid hormone and its analogs, vitamin D supplements > 1000 IU/day, (inhaled or topical glucocorticoids used more than 2 weeks before screening are allowed), anabolic steroids, calcitriol and its analogs, thiazide diuretics within 6 months prior to the first administration; bisphosphonates, fluoride for the treatment of osteoporosis within 12 months prior to the first administration; denosumab or any cathepsin K inhibitor within 18 months prior to the first administration; prior use of Romosozumab (including Evenity and other biosimilars); any prescription drugs or Chinese herbal medicines within 4 weeks prior to the first administration; any over-the-counter drugs and food supplements (including vitamins, calcium supplements, health food products, etc.) within 2 weeks prior to the first administration.
  7. Drug or substance abuse, alcoholism or heavy smoking: history of drug or substance abuse, or positive result in drug abuse screening at the time of screening; average weekly alcohol consumption > 14 units within 3 months prior to screening (1 unit ≈ 17.7 mL ethanol, i.e., 1 unit ≈ 360 mL beer with 5% alcohol content, or 45 mL Baijiu (liquor) with 40% alcohol content, or 150 mL wine with 12% alcohol content), or positive alcohol test result at screening, or inability to completely abstain from any food or beverage containing alcohol during the hospitalization period; average daily cigarette consumption > 5 sticks within 3 months prior to screening, or inability to completely abstain from any tobacco products during the hospitalization period; average daily caffeine intake > 500 mg within 3 months prior to screening (equivalent to 5 cups of tea or coffee, or 8 cans of soda or other caffeinated products).
  8. Blood donation (including component blood donation) or blood loss ≥ 400 mL within 3 months prior to screening; blood donation (including component blood donation) or blood loss ≥ 200 mL or blood transfusion within 1 month prior to screening; or plan to donate blood or blood components during the study period or within 1 month after the end of the study.
  9. Difficulty in blood collection or inability to tolerate multiple venipunctures; or a history of clinically significant needle phobia or hematophobia as judged by the investigator.
  10. Vaccination with , live attenuated vaccines or any vaccine containing live viral components within 3 months prior to screening; or plan to receive the above vaccines during the study period or within 1 month after the end of the study.
  11. Severe trauma or major surgery requiring general anesthesia within 3 months prior to screening; or plan to undergo surgery (except for surgery under local anesthesia) within 3 months after the last administration.
  12. Participation in any interventional clinical study (including drugs or vaccines, as well as other clinical studies of the study drug or other cohorts of this study) and receipt of investigational drugs within 3 months prior to screening, or current participation in such studies.
  13. Other diseases or medical histories that are clinically significant or may prevent the subject from completing the study, or other diseases or medical histories that may significantly alter drug absorption, metabolism or excretion, as judged by the investigator.
  14. Any other reasons that make the subject unsuitable for participation in this study, as judged by the investigator.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
118 participants (estimated)

Study arms

  • Experimental
    Test Group

    Drug: SAL0123 105mg:1.17ml

    Drug: SAL0123

  • Active comparator
    Reference Group

    Drug: Romosozumab 105mg:1.17ml

    Drug: Romosozumab

Interventions

  • DrugSAL0123

    Dosage Form: Injection Specification: 105mg:1.17ml Dosage and Administration: 2 vials of 105 mg: 1.17 mL each, subcutaneous injection in the upper arm and abdomen Treatment Duration: Single subcutaneous injection of 2 vials on Day 1

  • Dosage Form: Injection Specification: 105mg:1.17ml Dosage and Administration: 2 vials of 105 mg: 1.17 mL each, subcutaneous injection in the upper arm and abdomen Treatment Duration: Single subcutaneous injection of 2 vials on Day 1

06

What researchers measure

Primary outcomes

  1. PK parameters( Cmax)

    Time frame: Within a single dosing period ( from pre-dose up to 85 days post-dose)

  2. PK parameters( AUCinf)

    Time frame: Within a single dosing period ( from pre-dose up to 85 days post-dose)

07

Study locations

1 site
  • The Second Hospital of Anhui Medical University Clinical Pharmacology Research Center
    Hefei, Anhui 230601, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Feb 2026, 3 months after the start.

Of 30 phase 1 interventional studies under Osteoporosis, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 22. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Feb 3, 2026
StartActual
Oct 19, 2025
Primary completionEst.
Feb 5, 2026
CompletionEst.
Feb 5, 2026
Last update
Feb 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07384104
Collaborators
Salubris (Chengdu) Biotechnology Co., Ltd., Salubris (Suzhou) Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Feb 3, 2026
Start date
Oct 19, 2025
Primary completion
Feb 5, 2026 (estimated)
Completion
Feb 5, 2026 (estimated)
Last update
Feb 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion